Thromb Haemost 1996; 75(05): 757-759
DOI: 10.1055/s-0038-1650362
Original Article
Schattauer GmbH Stuttgart

Simple and Rapid Detection of Factor V Leiden by Allele-specific PCR Amplification

Rainer Blasczyk
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
,
Markus Ritter
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
,
Christian Thiede
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
,
Jenny Wehling
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
,
Günter Hintz
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
,
Andreas Neubauer
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
,
Hanno Riess
The Department of Internal Medicine, Division of Hematology and Oncology, Virchow-Klinikum, Humboldt-Universitat zu Berlin, Germany
› Author Affiliations
Further Information

Publication History

Received 13 December 1995

Accepted after revision 23 January 1996

Publication Date:
10 July 2018 (online)

Preview

Summary

Resistance to activated protein C is the most common hereditary cause for thrombosis and significantly linked to factor V Leiden. In this study, primers were designed to identify the factor V mutation by allele-specific PCR amplification. 126 patients with thromboembolic events were analysed using this technique, PCR-RFLP and direct sequencing. The concordance between these techniques was 100%. In 27 patients a heterozygous factor VGln506 mutation was detected, whereas one patient with recurrent thromboembolism was homozygous for the point mutation. Due to its time- and cost-saving features allele-specific amplification should be considered for screening of factor VGln506.